IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients

- Data presented at 44th American Society of Clinical Oncology (ASCO) annual meeting further supports improvement in median survival vs. external controls -

IRVINE, Calif., June 02, 2008 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. today announced follow-up results from the Phase 2 study of IDM-2101 showing that the product candidate was well tolerated, induced broadly specific cytotoxic T lymphocyte (CTL) responses, and showed a positive survival trend in HLA-A2 positive patients with non-small cell lung cancer (NSCLC) who were treated with IDM-2101, compared to a parallel external control group of HLA-A2 negative non-treated patients.

"We continue to be encouraged by the positive trend in overall survival we are seeing in patients treated with IDM-2101," said Minal Barve, M.D., practice director, Mary Crowley Cancer Research Center. "Based on the results to date, further clinical study is warranted to confirm the potential of IDM-2101 as a treatment option for patients with non-small cell lung cancer."

Trial Design and Results

The Phase 2 open label, non-randomized trial, was designed to assess one-year patient survival, overall survival and vaccine immunogenicity in HLA-A2 positive patients with stage IIIb, IV or recurrent NSCLC. Patients were required to have tumor volume less than 125 cm2 with no limits on prior chemotherapy. Sixty-eight patients were enrolled in the trial (sixty-three treated with one or more doses) with the last patient enrolled in March 2006. Patients are still being followed for long-term survival.

    Results are as follows:


    --  One-year survival IDM-2101 patients versus HLA-A2 negative patients

        (n=72) but otherwise comparable group -- 60 percent versus 49 percent.

    --  Median survival (IDM-2101 versus comparator group) -- 17.3 months

        versus 12.0 months.

    --  Stable disease >/= 3 months -- 54 patients (86%) treated with

        IDM-2101.

    --  Tumor Response IDM-2101 -- One patient had complete response; one

        patient had partial response.

    --  17 patients (27%) treated with IDM-2101 continued treatment for one

        year with no evidence of progressive disease

    --  14 patients (22%) treated with IDM-2101 continued treatment for two

        years with no evidence of progressive disease

    --  Measurable immune response - 91 percent of patients treated with

        IDM-2101, who were tested for immune response, had a measurable

        response to at least one of the epitopes included in the vaccine

        with 64 percent responding to at least three of the epitopes.

    --  Toxicities attributable to the vaccine were mild and consisted

        primarily of injection site reactions.


"These results further support the survival trend and safety of IDM-2101 and will serve as a basis in determining an appropriate clinical pathway for this important treatment," said Timothy P. Walbert, president and chief executive officer, IDM Pharma, Inc.

About IDM-2101

IDM-2101 includes nine CTL epitopes from four tumor associated antigens (TAA) including two proprietary native epitopes and seven modified, or analog, epitopes and one universal epitope a source of T-cell help. Tolerance to TAA, which is a failure of the immune system to recognize the cancer as diseased tissue, is broken by using these analog epitopes which enhance the potency of the T cell response. The Phase 2 IDM-2101 study has been ongoing since late 2004 and patient treatment has been completed. Long-term follow-up is ongoing for overall survival.

About Lung Cancer

Lung cancer continues to be a major health problem with a very high mortality rate and represents the leading cause of cancer death in the United States. According to the American Cancer Society, approximately 213,000 new lung cancer cases will be diagnosed in the United States in 2007, and an estimated 160,000 patients will die from lung cancer. The American Cancer Society also estimates that non-small cell lung cancer represents 87 percent of all lung cancers.

In the European Union, non-small cell lung cancer represents 75 percent of all lung cancer. In addition, approximately 130,000 new cases will be diagnosed in 2007 in the top five markets (France, Germany, Italy, UK & Spain)

About IDM Pharma

IDM Pharma is focused on the development of innovative cancer products that either destroy cancer cells by activating the immune system or prevent tumor recurrence by triggering a specific adaptive immune response. IDM Pharma is dedicated to maximizing the full therapeutic and commercial potential of each of its innovative products to address the needs of patients and the physicians who treat these patients.

As previously announced, the Company is evaluating the Company's research and development programs, including related assets and costs, and strategic alternatives available to the Company.

For more information about the company and its products, visit http://www.idm-pharma.com.

Forward-Looking Statements

This press release includes and the presentation described in this press release will include forward-looking statements that reflect management's current views of future events including statements regarding the Phase 2 IDM-2101 study, the support that the survival data and positive safety profile and immunological data from the Phase 2 IDM-2101 provides for further clinical evaluation of IDM-2101, the potential for IDM-2101 as a treatment for non-small cell lung cancer and the Company's plans to evaluate strategic alternatives. Actual results may differ materially from the forward-looking statements due to a number of important factors, including, but not limited to, whether the Company or any of its collaborators will be able to develop pharmaceutical products using the technologies of the Company, whether clinical trial results to date are predictive of results of any future clinical trials, risks associated with completing clinical trials of product candidates, risks involved in the regulatory approval process for the Company's product candidates, the possibility that clinical testing may reveal undesirable and unintended side effects or other characteristics that may prevent or limit the commercial use of proposed products, the Company's dependence on intellectual property, whether the Company will be able to complete any potential strategic transaction on terms acceptable to the Company's stockholders, and whether the cash resources of the Company will be sufficient to fund operations as planned, including any further clinical trials of any of the Company's product candidates, including IDM-2101. These and other risks affecting the Company and its drug development programs, intellectual property rights, personnel and business are more fully discussed in the Company's Quarterly Report on Form 10-Q filed with the SEC for the quarter ended March 31, 2008 and other periodic reports filed with the SEC. The Company expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

CONTACT: Bob De Vaere, Chief Financial Officer of IDM Pharma, Inc.,+1-949-470-6447; or Geoff Curtis of WeissComm Partners, cell,+1-312-550-8138, , for IDM Pharma, Inc. gcurtis@wcpglobal.com

Web site: http://www.idm-pharma.com/

Ticker Symbol: (NASDAQ-NMS:IDMI)

Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: June 2008

View comments

Hide
(web2)